These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Cancers exhibit a mutator phenotype: clinical implications. Loeb LA; Bielas JH; Beckman RA Cancer Res; 2008 May; 68(10):3551-7; discussion 3557. PubMed ID: 18483233 [TBL] [Abstract][Full Text] [Related]
26. Molecular biology of thyroid neoplasms. Satta MA; Nanni S; Della Casa S; Pontecorvi A Rays; 2000; 25(2):151-61. PubMed ID: 11370534 [TBL] [Abstract][Full Text] [Related]
27. Can chromosomal instability initiate tumorigenesis? Michor F; Iwasa Y; Vogelstein B; Lengauer C; Nowak MA Semin Cancer Biol; 2005 Feb; 15(1):43-9. PubMed ID: 15613287 [TBL] [Abstract][Full Text] [Related]
28. Genetic susceptibility to cancer. ICRP publication 79. Approved by the Commission in May 1997. International Commission on Radiological Protection. Ann ICRP; 1998; 28(1-2):1-157. PubMed ID: 10406427 [TBL] [Abstract][Full Text] [Related]
29. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. Olivier M; Hussain SP; Caron de Fromentel C; Hainaut P; Harris CC IARC Sci Publ; 2004; (157):247-70. PubMed ID: 15055300 [TBL] [Abstract][Full Text] [Related]
30. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Brabletz T; Jung A; Spaderna S; Hlubek F; Kirchner T Nat Rev Cancer; 2005 Sep; 5(9):744-9. PubMed ID: 16148886 [TBL] [Abstract][Full Text] [Related]
31. Oncogenes and antioncogenes involved in human thyroid carcinogenesis. Lazzereschi D; Mincione G; Coppa A; Ranieri A; Turco A; Baccheschi G; Pelicano S; Colletta G J Exp Clin Cancer Res; 1997 Sep; 16(3):325-32. PubMed ID: 9387909 [TBL] [Abstract][Full Text] [Related]
33. Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Spaderna S; Schmalhofer O; Hlubek F; Jung A; Kirchner T; Brabletz T Verh Dtsch Ges Pathol; 2007; 91():21-8. PubMed ID: 18314592 [TBL] [Abstract][Full Text] [Related]
34. Nutrient-sensitive, antagonistically pleiotropic genes and their contribution to malignant behavior. McBride SM; Haas-Kogan DA Med Hypotheses; 2008; 70(2):444-53. PubMed ID: 17689876 [TBL] [Abstract][Full Text] [Related]
35. Common gene polymorphisms, cancer progression and prognosis. Loktionov A Cancer Lett; 2004 May; 208(1):1-33. PubMed ID: 15105042 [TBL] [Abstract][Full Text] [Related]
36. The transition of benign to malignant in epithelial and mesenchymal tumours. Koten JW; Den Otter W Anticancer Res; 1991; 11(2):567-8. PubMed ID: 2064312 [TBL] [Abstract][Full Text] [Related]
37. [The human E-cadherin/catenin complex: a potent invasion and tumor suppressor]. Mareel M; Van Roy F Verh K Acad Geneeskd Belg; 1998; 60(6):567-98. PubMed ID: 10230325 [TBL] [Abstract][Full Text] [Related]
38. Gastrointestinal stromal tumours. Miettinen M; Sarlomo-Rikala M; Lasota J Ann Chir Gynaecol; 1998; 87(4):278-81. PubMed ID: 9891765 [TBL] [Abstract][Full Text] [Related]
39. Recurrent phyllodes tumours of the breast: pathological features and clinical implications. Tan EY; Tan PH; Yong WS; Wong HB; Ho GH; Yeo AW; Wong CY ANZ J Surg; 2006 Jun; 76(6):476-80. PubMed ID: 16768772 [TBL] [Abstract][Full Text] [Related]
40. Tumour progression: random mutations or an integrated survival response to cellular stress conserved from unicellular organisms? Israel L J Theor Biol; 1996 Feb; 178(4):375-80. PubMed ID: 8733476 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]